Azacitidine Post-transplant Maintenance Improves Disease Progression in High-Risk Acute Myeloid Leukemia and Myelodysplastic Syndrome
CONCLUSION: AZA maintenance was associated with a lower progression rate in patients with high-risk FLT3-negative AML or MDS, and AZA maintenance should be considered for post-alloHCT maintenance in this subset.PMID:38403505 | DOI:10.1016/j.clml.2024.01.012
Source: Clinical Lymphoma and Myeloma - Category: Cancer & Oncology Authors: Oren Pasvolsky Rima M Saliba Uday R Popat Amin Alousi Rohtesh Mehta Jason Yeh Gheath Al-Atrash Masood Adeel Jeremy Ramdial David Marin Gabriela Rondon Partow Kebriaei Richard Champlin Naval Daver Courtney Dinardo Nicholas J Short Elizabeth J Shpall Bet ΓΌ Source Type: research
More News: Acute Leukemia | Acute Myeloid Leukemia | Cancer & Oncology | Clinical Trials | Leukemia | Lymphoma | Myelodysplastic Syndrome | Myeloma | Study | Transplants